EX-10.46 16 shc20221231_exhibitx10x46.htm EX-10.46 Document
Exhibit 10.46
[Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K and marked with asterisks. The omitted information is (i) not material and (ii) the type that the registrant treats as private or confidential.]
Willowbrook: Group Settlement Term Sheet

Pursuant to this binding short form Term Sheet (“Term Sheet”), the Parties agree to the following terms in full and final resolution of the Covered Claims:

1.Documentation.

a.The parties intend this to be a binding Term Sheet, and that it will become binding once it has been executed by an authorized representative from each member of the PEC, as well as by counsel for Sotera Health Company, Sotera Health LLC and Sterigenics U.S., LLC.

b.An authorized representative from each PEC law firm must sign and agree to the terms reflected in the Term Sheet by no later than Monday, January 9, 2023.

c.The Parties signing below (“Parties”) agree to work in good faith to draft and execute a full settlement agreement in accordance with this Term Sheet (“Settlement Agreement” or “Willowbrook Group Settlement Agreement”). The Settlement Agreement is subject to the approval of all of the Parties. The failure to execute a full Settlement Agreement does not impact the binding effect of this Term Sheet.

d.Settling Defendants (as defined below) expressly deny any and all liability. Nothing in this Term Sheet, including the qualified settlement fund amount, is an admission of any alleged fact, liability or fault, or that the use and/or emission of ethylene oxide by and/or from Sterigenics US’s operations in or around Willowbrook, Illinois has ever caused or created safety hazards or health risks of any sort to the surrounding community.

2.Definitions.

a.The word “Plaintiffs” refers to all persons who are plaintiffs with a Covered Claim as of the date this Term Sheet is signed, and includes any additional persons who have become plaintiffs at the time the Settlement Agreement is signed, but does not include those listed on Appendix C. The list of Plaintiffs covered by this Term Sheet is set forth in Appendix A to this Term Sheet, and will be updated by PEC to include any additional persons who have become plaintiffs at the time the Settlement Agreement is signed.

b.The phrase “Clients with Unfiled Claims” refers to individuals who have retained Plaintiffs’ Counsel in connection with a Covered Claim as of the date this Term Sheet is signed, but who have not filed a lawsuit against any of the Released Parties. “Clients with Unfiled Claims” includes any additional individuals who retain Plaintiffs’ Counsel in connection with a Covered Claim after the signing of the Term Sheet and have not yet filed a lawsuit against any of the Released Parties at the time the Settlement Agreement is signed. The list of Clients with Unfiled Claims is set forth in Appendix B to this Term Sheet, and will be updated by PEC to include any additional “Clients with Unfiled Claims” at the time the Settlement Agreement is signed. PEC will in good faith work to finalize retention by any and all potential clients and supplement Appendices A and B accordingly, by the date the Settlement Agreement is signed.

c.The term “PEC” refers to the Plaintiffs’ Executive Committee, which is composed of the following firms: Salvi, Schostock & Pritchard, PC; Romanucci & Blandon, LLC; Hart McLaughlin & Eldridge, LLC; The Collins Law Firm, PC; Smith LaCien, LLP; Tomasik Kotin Kasserman, LLC and Miner Barnhill & Galland, PC.

d.The term “Non-PEC Firms” refers to any and all law firms representing Eligible Claimants that are not members of the PEC.

e.The phrase “Plaintiffs’ Counsel” refers to the law firms representing Eligible Claimants, including the PEC and Non-PEC Firms; a list of those law firms is set forth in Appendix D to this Term Sheet. PEC have represented that they are negotiating this Term Sheet on behalf of Plaintiffs’ Counsel and each of their clients who is a specific Eligible Claimant and is identified in Appendices A and B.

f.“Sotera Health” refers to Sotera Health Company, Sotera Health Holdings, LLC, Sotera Health LLC, Sotera Health Topco Parent, LP, and Sotera Health GP, LLC.

g.“Sterigenics US” refers to Sterigenics U.S., LLC and all of its predecessor and successor entities.




h.“GTCR” refers to GTCR LLC, GTCR L.L.C., and GTCR Golder Rauner II, L.L.C.; all funds associated with GTCR LLC, GTCR L.L.C., and GTCR Golder Rauner II, L.L.C., including without limitation GTCR Fund IX/A, L.P., GTCR Fund IX/B, L.P., GTCR Co-Invest III, L.P., GTCR Fund XI/A LP, GTCR Fund XI/CLP, GTCR Partners XI/A&C LP, GTCR Co-Invest XI LP, GTCR Investment XI LLC, GTCR Fund XI/A VCOC, GTCR Fund XI/C VCOC; and the respective affiliates, managers, limited partners, and members of (i) GTCR LLC, GTCR L.L.C., GTCR Golder Rauner II, L.L.C., and (ii) the funds associated with GTCR LLC, GTCR L.L.C., and GTCR Golder Rauner II, L.L.C.

i.“Warburg Pincus” refers to Warburg Pincus LLC and all funds, general partners and management companies associated with or managed by Warburg Pincus LLC or its affiliates, including without limitation Warburg Pincus Private Equity XI, LP, Warburg Pincus Private Equity XI-B, LP, Warburg Pincus Private Equity XI-C, LP, Warburg Pincus XI Partners, LP, WP XI Partners, LP, Warburg Pincus XI, LP, WP Global, LLC, Warburg Pincus Partners I, LP, Warburg Pincus GP LLC, Warburg Pincus (Cayman) XI, LP, Warburg Pincus XI-C, LLC, Warburg Pincus Partners II (Cayman), LP, Warburg Pincus (Bermuda) Private Equity GP Ltd., Warburg Pincus & Co., WP XI, LP, Bull Co-Invest, LP, Warburg Pincus Private XI, LP, Warburg Pincus Partners II, LP, Warburg Pincus Partners II Holdings, LP, Warburg Pincus Partners GP LLC, Warburg Pincus Partners II Holdings (Cayman), LP, WPP II Administrative (Cayman), LLC and their respective affiliates, members, officers, directors, partners, and limited partners.

j.The phrase “Settling Defendants” refers to Sotera Health LLC and Sterigenics U.S., LLC.
k.The phrase “Eligible Claimants” refers to the Plaintiffs and Clients with Unfiled Claims, as reflected on Appendices A and B, as supplemented to add any additional plaintiffs or retained clients.

l.The phrase “Covered Claims” refers to the following categories of claims:

i.All claims, past, present, and future, alleged or that could have been alleged for any injury, harm, or damages, and seeking any form of relief, including money damages, restitution, punitive or exemplary damages, injunctive relief, or any other form of relief, related to or arising from alleged use and/or emissions of ethylene oxide from Sterigenics US’s operations in or around Willowbrook, Illinois (“Willowbrook Claims”), including but not limited to all claims against Sterigenics US as successor to Sterigenics EO, Inc., IBA S&I, Inc., Griffith Micro Science, Inc., Micro-Biotrol, Inc., and Micro-Biotrol Company related to the operations of any of those companies in or around Willowbrook, Illinois; and

ii.All claims, past, present, and future, alleged or that could have been alleged in the Bachoe et al. v. Sotera Health Company, et al. action filed on November 1, 2022 in the Circuit Court of Cook County (Case No. 2022-L- 009825), the Bachoe et al. v. Sotera Health Company, et al. action now pending in the U.S. District Court for the Northern District of Illinois (Case No. 22-cv-06292), and any other actual or potential actions seeking to challenge any transfer of assets to or from Sterigenics U.S., LLC, Sotera Health LLC, or any other Released Parties to any other entity or person.

m.The phrase “Other Facility Claims” refers to claims by any individual or entity relating to any other facility (other than a facility in or around Willowbrook, Illinois) owned or operated by any Released Parties and for which Plaintiffs’ Counsel serves as counsel of record or referral counsel. A list of all Other Facility Claims will be provided to Settling Defendants as Appendix G by no later than January 27th, 2023. PEC represents and warrants that they are not currently pursuing any Other Facility Claims, regardless of whether they are counsel of record or referral counsel, other than those listed on Appendix G.

n.The phrase “Released Parties” refers to Sotera Health, Sterigenics US, Warburg Pincus, GTCR, and all their affiliates, predecessors, successors, direct or indirect parents, direct or indirect subsidiaries, assigns, as well as any current, former, direct or indirect partners, managers, members, shareholders, employees, directors, officers, management companies, incorporators, investors, landlords, tenants, suppliers, service providers, customers, consultants, attorneys, agents, declarants, affiants or other representatives, including without limitation [***]. Released Parties also refers to the Released Parties’ insurers, including without limitation Steadfast Insurance Company/Zurich Insurance Group and National Union/AIG.

o.The phrase “Good Faith Settlement” refers to a settlement per the terms of this Term Sheet that is approved by the Circuit Court of Cook, Illinois, County Law Division, as having been entered into in good faith, pursuant to 740 ILCS 100/2.

3.Establishment of Settlement Program




a.PEC represents and warrants that the lists of Plaintiffs and Clients with Unfiled Claims reflected in Appendices A and B is complete and accurate. PEC represents and warrants that there are 870 Eligible Claimants, as reflected on Appendices A and B. PEC further affirm that they have not been retained by any individuals with Covered Claims other than those identified in Appendices A, B, and C, and PEC are not aware of any other individuals who have filed or plan to file Covered Claims.

b.The Parties will cooperate in establishing a Settlement Program and associated documents that comply in all respects with applicable state Rules of Professional Responsibility regarding aggregate settlements including Illinois Rule of Professional Conduct 1.8(g).

c.By participating in the Settlement Program and obtaining a settlement allocation for Eligible Claimant client(s), a Non-PEC Firm agrees to:

i.the Settlement Program Procedures set forth in Paragraph 4 below, including the requirement to provide information regarding Opt-Outs and any client whose status is uncertain, as if the Non-PEC Firm was a PEC member;

ii.the Confidentiality terms described in Paragraph 10 below, including the agreement not to identify Settling Defendants or Released Parties by name in any marketing communications, including websites, as if the Non-PEC Firm was a PEC member; and

iii.other conditions mutually agreed-upon by the Settling Defendants and PEC.

d.The Parties agree to cooperate in seeking a Court Order that facilitates the administration of the Settlement Program and the Settling Defendants’ evaluation of Opt-Outs, including by requiring Non-PEC Firms to comply with Settlement Program Procedures as a condition of participating in the Settlement Program.

e.The associated documents to be prepared by the Parties will include a release of Covered Claims (“Release”) for execution by individual Eligible Claimants who choose to accept their settlement allocation. Eligible Claimants who accept their settlement allocation and execute the Release will be “Settling Claimants”.

f.In the Release, Settling Claimants shall agree to release and covenant not to sue the Released Parties for all Covered Claims and any claims that are or could have been brought against any Released Parties relating to the Covered Claims or based on the conduct alleged in the litigation relating to any Covered Claims.

i.The Settling Claimants shall further expressly acknowledge and agree to release any rights they may have regarding claims relating to or arising from any Covered Claims that the Settling Claimant does not know or suspect to exist in his or her favor at the time of executing the Release and that, if known by him or her, would have materially affected his or her settlement with the Released Parties. The Settling Claimants expressly and knowingly waive any statutory or judicial provisions, rulings, or mandates to the contrary.

ii.Settling Claimants further agree to release all claims, past, present, and future, alleged or that could have been alleged against insurers who have any of the Released Parties as a Named Insured, including but not limited to Steadfast Insurance Company/Zurich Insurance Group and National Union/AIG, relating to or arising from any Covered Claims. For avoidance of doubt, Released Parties maintain, and do not release, any claims they may have against their insurers.

g.The Release will further require that, if any Settling Claimant settles with any third party against whom claims are not released through this settlement (collectively, “Non-Settling Third Parties”), the Settling Claimant will obtain a release from the Non-Settling Third Party for Released Parties for any claim for indemnity, contribution, or similar theory. If any Settling Claimant obtains a judgment against any Non-Settling Third Party, such Settling Claimant will not execute on any portion of that judgment that the Non-Settling Third Party successfully seeks from Released Parties via a claim for indemnity or contribution or similar claim. Settling Claimants agree to indemnify Released Parties for any claims for indemnity or contribution brought by any Non-Settling Third Parties against Released Parties arising from or relating to Settled Claims.

h.The Settlement Agreement will contain provisions that require all Plaintiffs’ Counsel, subject to the exercise of their independent professional judgment, to recommend participating in the settlement to each of his/her clients.

4.Settlement Program Procedures




a.The Settlement Program shall include a Claims Administrator who will serve in a capacity as determined by the PEC, to include evaluating appropriate documentation and applying a claim valuation formula or matrix to determine each Eligible Claimant’s settlement allocation amount. The Settlement Program shall also include an Administrator of the Qualified Settlement Fund (“QSF”) who will be responsible for distributing the settlement funds to be paid to each Settling Claimant. The QSF Administrator and the Claims Administrator may be the same person.

b.The Claims Administrator and QSF Administrator will be selected by the PEC.

c.Each Eligible Claimant will receive notice of their individual settlement allocation amount along with the other disclosures, including any required by Illinois Rule of Professional Conduct 1.8(g). Within 30 days of receiving all required disclosures along with their individual settlement allocation amount as determined by the Claims Administrator, each Eligible Claimant who chooses to accept their settlement allocation and become a Settling Plaintiff must execute the agreed upon Release (“Opt In Deadline”).

i.PEC can request a 30-day extension of the Opt In Deadline, which will not be unreasonably denied.

d.No later than three (3) days after the Opt In Deadline, PEC will confer with the Claims Administrator to prepare a written list of: (a) Settling Claimants; (b) those Eligible Claimants who have indicated that they have declined to accept their settlement allocation or the terms of the Release (“Opt-Out”); and (c) those Eligible Claimants whose status is unclear (for example, because the relevant Plaintiffs’ Counsel can no longer locate the Claimant or because the Claimant has ceased communicating with the relevant Plaintiffs’ Counsel). The written list shall be provided to the Settling Defendants no later than five (5) days after the Opt In Deadline.

e.The Claims Administrator will retain all executed Releases for the Settling Claimants until it is determined whether the Settling Defendants will be proceeding with the settlement or exercising its option to walk away from and void the settlement due to insufficient participation by the Eligible Claimants. The Claims Administrator must receive an executed Release from the Settling Claimant before any Settlement Funds may be paid to that Settling Claimant.

f.For each Opt-Out, Plaintiffs’ Counsel will complete a Plaintiff Fact Sheet (attached as Appendix E to this Term Sheet) and, to the extent applicable, the Mental Health Addendum (attached as Appendix F to this Term Sheet) and provide it to Settling Defendants within 15 days of the Opt In Deadline.

g.For each Eligible Claimant whose status is unclear as described in Paragraph 4(d) above, Plaintiffs’ Counsel will complete a Plaintiff Fact Sheet and, to the extent applicable, the Mental Health Addendum, to the best of their ability based on information in their possession and provide it to Settling Defendants within 15 days of the Opt In Deadline.

5.Participation.

a.Settling Defendants will have the absolute option, in their sole discretion, to walk away from and void the settlement unless 99% of Eligible Claimants represented by the PEC opt into the settlement.

b.Settling Defendants will have the absolute option, in their sole discretion, to walk away from and void the settlement unless 95% of the Claimants represented by Non- PEC Firms opt into the settlement.
c.If any Opt-Out fits into one or more of the following categories, then Settling Defendants will have the absolute option to walk away from and void the settlement:

i.Any Eligible Claimant alleging ethylene oxide exposure at any location (e.g., residences, workplaces, schools, etc.) closer than two miles from the Willowbrook facility (as the crow flies) and a cancer injury;

ii.Any Eligible Claimant alleging ethylene oxide exposure at any location (e.g., residences, workplaces, schools, etc.) closer than three miles from the Willowbrook facility (as the crow flies) and a breast cancer or hematopoietic cancer injury;

iii.Any Eligible Claimant alleging ethylene oxide exposure at any location (e.g., residences, workplaces, schools, etc.) closer than two miles from the Willowbrook facility (as the crow flies) and more than one miscarriage;




iv.Any Eligible Claimant alleging ethylene oxide exposure at any location (e.g., residences, workplaces, schools, etc.) closer than two miles from the Willowbrook facility (as the crow flies) and any injury to reproductive health besides miscarriage (including, but not limited to, infertility, stillbirth, premature birth, or birth defect);

v.Any Eligible Claimant alleging ethylene oxide exposure between 1984 and 1989 at any location (e.g., residences, workplaces, schools, etc.) closer than three miles from the Willowbrook facility (as the crow flies);

vi.Any Eligible Claimant alleging ethylene oxide exposure for 5 years or more at any location (e.g., residences, workplaces, schools, etc.) closer than three miles from the Willowbrook facility (as the crow flies); or

vii.Any Eligible Claimant alleging ethylene oxide exposure for 10 years or more at any location (e.g., residences, workplaces, schools, etc.) closer than four miles from the Willowbrook facility (as the crow flies).

d.After receiving the information described in Paragraph 4(d)-(g) above, Settling Defendants will have 15 days to evaluate the information provided (“Settling Defendants’ Review Period”) and, if applicable, to exercise its walk-away rights described in subsections (a)-(c) above, or elect to proceed with the settlement and waive the requirements of subsections (a)-(c) above. At the expiration of the Settling Defendants’ Review Period, Settling Defendants will notify the PEC and Claims Administrator of their decision whether to proceed with the settlement, if applicable. In the event the participation criteria have been met or, if applicable, Settling Defendants elect to proceed with the settlement (“Settling Defendants’ Decision to Proceed”), the settlement will be binding on all Settling Claimants who accepted their settlement allocation and submitted a Release.

e.Plaintiffs’ Counsel represent and warrant that there are 870 Eligible Claimants, as reflected on Appendices A and B. Settling Defendants will have the absolute option, in their sole discretion, to walk away from and void the settlement if it is determined based on the claim formulation or matrix that 40 or more Eligible Claimants do not have valid claims or are otherwise deemed not entitled to any recovery.

f.In addition to the walk-away rights described above in sections 5(a)-(e), Settling Defendants will have the absolute option, in their sole discretion, to walk away from and void the settlement if, before the final funding date for the QSF (as defined below), they learn of more than 5 other Willowbrook claims by Plaintiffs’ Counsel, not listed in Appendix A or B, against any of the Released Parties relating to any Covered Claim(s).

g.Any disagreement or dispute between the parties involving the participation level or percentage participation of claimants described in this Paragraph will be resolved by the parties submitting any such disagreement or dispute to Miles Ruthberg, whose resolution of the dispute will be final.

6.Funding Amount and Procedure.

a.The amount of settlement funds for the Settlement Program will be $285.5 million (“Settlement Funds”).

b.The Parties will establish an escrow account (“Escrow Account”). Settling Defendants will select the institution (“Escrow Agent”) to hold the Escrow Account with PEC’s consent, which will not be unreasonably withheld. The Parties will cooperate to prepare an escrow agreement with instructions to the Escrow Agent consistent with the obligations set forth in this Term Sheet.

c.The Parties will also establish an interest-bearing qualified settlement fund (“QSF”). PEC will select the financial institution to hold the qualified settlement fund with Settling Defendants’ consent, which will not be unreasonably withheld. The QSF shall be treated as being at all times a “qualified settlement fund” for US federal income tax purposes, and the Parties shall act accordingly.

d.Sterigenics U.S., LLC is exclusively responsible for paying the Settlement Funds to the Escrow Account.

e.Sotera Health Company agrees to be guarantor of Sterigenics U.S., LLC’s obligation to pay the Settlement Funds to the Escrow Account until said funds are deposited into the Escrow Account.

f.Sterigenics U.S., LLC will deposit the Settlement Funds in the Escrow Account or transmit the Settlement Funds to the designated Escrow Agent to be deposited into the Escrow Account by or on May 1, 2023, subject to the conditions set forth below in subsection (h).




g.Subject to the conditions set forth in subsection (h), the Escrow Agent will release the Settlement Funds from the Escrow Account to the QSF within 30 days of the final order on appeal affirming the GFSD (as defined below). If there is no appeal of the Court’s GFSD, the Escrow Agent will release the Settlement Funds to the QSF within 7 days of the expiration of the deadline to file an appeal from the Court’s GFSD, subject to the conditions set forth in subsection (h).

h.In the event of the failure of any of the conditions set forth below, the duties set forth in subsections (f) and (g) will be deferred until the conditions have been satisfied:
i.the continued operation of a stay on the actions set forth in Paragraph 8 below;
ii.the absence of any viable lawsuit challenging this Term Sheet or the Settlement Agreement; or
iii.compliance by PEC and Plaintiffs’ Counsel with all material duties and obligations set forth in this Term Sheet, the Settlement Agreement, and otherwise in connection with settlement.

i.In the event the Settling Defendants exercise their walk-away rights under this Term Sheet, or this Term Sheet otherwise becomes void, the duties set forth in subsections (f) and (g) are likewise void. In the event Sterigenics U.S., LLC has already deposited the Settlement Funds into the Escrow Account, those funds will be promptly returned by the Escrow Agent to Sterigenics U.S., LLC.

j.Any disagreement or dispute between the parties involving the conditions or obligations of the Parties described in this Paragraph will be resolved by the Parties submitting any such disagreement or dispute to Miles Ruthberg, whose resolution of the dispute will be final.

k.Fees incurred in connection with the administration of the Settlement Program, including fees of the Claims Administrator and any fees or costs associated with establishing and/or maintaining the QSF, are to be paid by Settling Claimants and/or Plaintiffs’ Counsel from the QSF, consistent with applicable state Rules of Professional Conduct.

l.Settling Defendants and their counsel have played no role in, will play no role in, and will neither take nor bear any responsibility for the allocation of Settlement Funds among the settling plaintiffs or the allocation of settlement funds between settling plaintiffs and Plaintiffs’ Counsel.

m.Sotera Health Company’s agreement to serve as guarantor of Sterigenics U.S., LLC’s obligation to pay the Settlement Funds to the Escrow Account does not constitute an admission of liability or responsibility as a parent company for the actions of Sterigenics U.S., LLC or any other subsidiary with respect to any of the Covered Claims.

7.Good Faith Settlement Determination and Funding

a.Upon satisfaction of the participation criteria set forth in Paragraphs 5(a)-(f), or the Settling Defendants elect to proceed with the settlement notwithstanding any walkaway rights triggered under Paragraphs 5(a)-(f), the parties will promptly file a motion for good-faith settlement determination (“GFSD”) pursuant to 740 ILCS 100/2,including an Ill. S. Ct. R. 304(a) finding.

b.The Parties will use best efforts to obtain a GFSD.

c.If a court does not enter a GFSD, or if the GFSD is overturned on appeal, the parties will return to mediation and use best efforts to resolve any issues.

8.Stay.

a.On January 9, 2023, the Parties will jointly seek a stay of (a) all pending cases related to the Covered Claims of Eligible Claimants listed on Appendices A and B for the purpose of finalizing the Settlement Agreement; and (b) the Bachoe et al. v. Sotera Health Company, et al. action now pending in the U.S. District Court for the Northern District of Illinois (Case No. 22-cv-06292).

b.The Parties will request the stays remain in place until the parties dismiss all pending Eligible Claims pursuant to Paragraph 9 below, or Settling Defendants walk away from the settlement pursuant to Paragraph 5(a)-(f).

c.The Parties’ agreement to the terms reflected in this Term Sheet is contingent on the grant of a stay as described in subsections (a)-(b) above.




d.In the event the Settling Defendants exercise their walk-away rights under this Term Sheet, or this Term Sheet otherwise becomes void, Plaintiffs may seek an immediate lifting of the stay set forth in 8(a).

9.Dismissal.

a.Settling Claimants who submitted a Release will dismiss with prejudice all their pending lawsuits and appeals within 10 days of the date the Escrow Agent releases the Settlement Funds for the Willowbrook Group QSF in Paragraph 6(g).

10.Confidentiality.

a.The Parties agree to maintain confidentiality of the fact of this Term Sheet, any Settlement Agreement, and the terms of such Term Sheet and Settlement Agreement, until the filing of a motion to obtain a stay of litigation. PEC also can discuss the fact, but not amount, of the settlement with Griffith Foods.

b.Eligible Claimants and PEC will not issue any press releases, press briefings, tweets, Instagram posts, or any other social media posts relating to the Term Sheet, any Settlement Agreement, or the terms of the Term Sheet and Settlement Agreement. PEC will not identify Settling Defendants or Released Parties by name in any marketing communications, including websites, but may otherwise discuss information in the public domain.

c.PEC acknowledge that Settling Defendants will be disclosing the principal terms of the overall settlement (including the total amount to be paid by the Settling Defendants) and may also disclose this Term Sheet and the Willowbrook Trial
Plaintiffs’ Term Sheet if the Settling Defendants determine that such disclosure is required by federal securities laws and regulations.

d.The Parties agree that while nothing in this Term Sheet is or will be intended to operate as a restriction on the right of PEC to practice law within the meaning of the relevant states’ equivalent to Rule 5.6(b) of the ABA Model Rules of Professional Conduct in any jurisdiction in which the firm may practice or whose Rules may otherwise apply, PEC represents that they and their respective law firm have no present intention to solicit, accept, or represent new clients for the purpose of bringing any Covered Claim against any Released Party.

e.The Parties agree that while nothing in this Term Sheet is or will be intended to operate as a restriction on the right of PEC to practice law within the meaning of the relevant states’ equivalent to Rule 5.6(b) of the ABA Model Rules of Professional Conduct in any jurisdiction in which the firm may practice or whose Rules may otherwise apply, PEC affirm that, to the best of their knowledge, they have ceased all firm-directed and direct advertising for Covered Claims and have no present intention to resume such advertising. This includes purchases of Google ad words, emails or other communications with client databases regarding Covered Claims and any other solicitation originating from any PEC in any medium, including television, billboards, websites, blogs, internet ads or pop-ups, newspapers, magazines, Facebook, Twitter, Instagram, or other social media outlets.

11.Attorneys’ Fees, Taxes, Liens and Rights of Subrogation.

a.Released Parties have no responsibility whatsoever for the payment of Settling Claimants’ attorneys’ fees or costs, or for the payment of any taxes owed by Settling Claimants, or for satisfaction of liens associated with allocations of funds.

b.Settling Claimants are solely responsible for their respective liens and will indemnify and hold harmless Settling Defendants and all Released Parties from claims by lienholders, actual or asserted.

c.The Parties will establish a process for identifying and resolving liens or subrogation or subrogated claims prior to the funding of the QSF.

d.Settling Claimants agree that any interest in, lien on, or right of subrogation in their Covered Claim by or belonging to any and all entities and individuals, including without limitation any governmental agencies or authorities, attorneys, litigation funders, healthcare providers, and/or insurers, will be satisfied by the Settling Claimant’s allocated payment.

e.Each PEC indemnifies and agrees to hold harmless each Settling Defendant and all Released Parties from any claim of any holder of a lien on PEC, to the extent such lien is applicable exclusively to Plaintiffs’ Counsel and not to any Settling Claimant.




f.Released Parties are not responsible for liens or subrogation claims against settlement payments or the costs and expenses incurred in resolving any such liens or subrogation claims against settlement payments.

12.Heirs.

a.For any wrongful death case, the Settling Claimant shall represent and warrant in their Release that they (a) are authorized to resolve the claim of the deceased Eligible Claimant on behalf of the heirs and estate of the deceased Eligible Claimant, (b) that they will ensure that the further allocation of the settlement funds related to the deceased Eligible Claimant’s claim is handled pursuant to applicable law, and (c) that they will indemnify the Released Parties against any claims related to the allocation of the settlement funds among the heirs and estate. The parties agree that Released Parties are entitled to rely on these representations.


13.The dates for commencing or completing of certain actions with this agreement are goals, and not necessarily deadlines. If a goal date or dates are not met on the precise date as set forth herein, the Parties will work together to adjust the timeline goals in order for the Parties to accomplish their agreed upon desire to complete this settlement.

14.With the exception of the Settling Defendants, and notwithstanding any other provision herein, none of the Released Parties has any obligation to the Settling Claimants, financial or otherwise, under this Term Sheet or otherwise as a result of or in consideration for the Settling Claimants opting into the settlement or for releasing and covenanting not to sue the Released Parties.

15.The Parties shall cooperate with respect to compliance with any required tax reporting, including by using reasonable efforts to provide (or to cause Plaintiffs’ Counsel, Plaintiffs, and Clients to provide) any information or tax forms reasonably requested by the Settling Defendants or the Claims Administrator. No amount of taxes shall be withheld by any person making a payment pursuant to the settlement in accordance with this Term Sheet except to the extent required by applicable law.

16.Governing Law. This Term Sheet shall be governed by and construed in accordance with the law of the State of Illinois without regard to any choice-of-law rules that would require the application of the law of another jurisdiction. Any such proceedings relating to this Term Sheet shall be filed in the Circuit Court of Cook County, Illinois.

17.Electronic Signatures. This Term Sheet and any amendments thereto, to the extent signed and delivered by means of a facsimile machine or electronic scan (including in the form of an Adobe Acrobat PDF file format), shall be treated in all manner and respects as an original agreement and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.

18.Counterparts. This Term Sheet may be executed in any number of counterparts, each of which shall be an original and all of which shall together constitute one and the same instrument. It shall not be necessary for any counterpart to bear the signature of all Parties. Counsel for any Party shall be authorized to assemble a composite counterpart which shall consist of one copy of each page, except the signature pages, together with multiple counterpart signature pages executed on behalf of every party to this Term Sheet. The composite counterpart may then be used by any Party for all purposes as the complete signed and executed Term Sheet.

[Continued on subsequent page]



Plaintiffs' Executive Committee, on Behalf of
Plaintiffs' Counsel

/s/ Antonio Romanucci
Antonio Romanucci
Romanucci & Blandin, LLC

/s/ Todd A. Smith
Todd A. Smith
Smith LaCien, LLP

/s/ Daniel M. Kotin
Daniel M. Kotin
Tomasik Kotin Kasserman, LLC

/s/ Shawn M. Collins
Shawn M. Collins
The Collins Law Firm, P.C.

/s/ Steven A. Hart
Steven A. Hart
Hart McLaughlin & Eldridge, LLC

/s/ Scott A. Entin
Scott Entin
Miner, Barnhill & Galland, P.C.

/s/ Patrick A. Salvi, II
Patrick A. Salvi, II
Salvi, Schostok & Pritchard P.C.

Settling Defendants

/s/ Matthew J. Klaben
Matthew J. Klaben
Sotera Health LLC
January 9, 2023

/s/ Matthew J. Klaben
Matthew J. Klaben
Sterigenics U.S., LLC
January 9, 2023

As Guarantor

/s/ Alexander Dimitrief
Alexander Dimitrief
Sotera Health Company
January 9, 2023

























Willowbrook: Group Settlement Term Sheet Appendix A



CLAIMANT NAME(S)CASE NUMBERFIRMDIAGNOSIS/DIAGNOSES**Filed After 1/19
1[***]18‐L‐011004Smith LacienBreast CancerNo
2[***]18‐L‐011252RB/HMEBreast CancerNo
3[***]19‐L‐009163CLF/MBGMultiple MyelomaNo
4[***]19‐L‐009167Smith LacienNHL & BreastNo
5[***]19‐L‐009167Smith LacienSchwanomaNo
6[***]19‐L‐009169Smith LacienBreast CancerNo
7[***]19‐L‐009170Salvi, Schostok & PritchardHodgkin's Lymphoma | Hashimotos |
Fertility Issues
No
8[***]19‐L‐009173Salvi, Schostok & PritchardNon‐Hodgkins LymphomaNo
9[***]19‐L‐009176Tomasik Kotin KassermanNon‐Hodgkin's LymphomaNo
10[***]19‐L‐009177Tomasik Kotin KassermanAcute Myeloid LeukemiaNo
11[***]19‐L‐009178Tomasik Kotin KassermanBreast CancerNo
12[***]19‐L‐009179Tomasik Kotin KassermanBreast CancerNo
13[***]19‐L‐009181RB/HMEBreast CancerNo
14[***]19‐L‐009182RB/HMEALLNo
15[***]19‐L‐009189Smith LacienBreast cancerNo
16[***]19‐L‐009190CLF/MBGMulitple MyelomaNo
17[***]19‐L‐009196RB/HMEAMLNo
18[***]19‐L‐009197Wise MorrisseyPancreatic CancerNo
19[***]19‐L‐009198RB/HMEBreast CancerNo
20[***]19‐L‐009200CLF/MBGBreast CancerNo
21[***]19‐L‐009202CLF/MBGMantle Cell Lymphoma (NHL)No
22[***]19‐L‐009205CLF/MBGMiscarriagesNo
23[***]19‐L‐009205CLF/MBGNHLNo
24[***]19‐L‐009206CLF/MBGBreast CancerNo
25[***]19‐L‐009207CLF/MBGBreast Cancer; MiscarriageNo
26[***]19‐L‐009213CLF/MBGALLNo
27[***]19‐L‐009214CLF/MBGBreast Cancer; MiscarriagesNo
28[***]19‐L‐009215CLF/MBGSezary Syndrome (NHL)No
29[***]19‐L‐009216CLF/MBGBreast CancerNo
30[***]19‐L‐009362Motherway & NapletonAmyloidosisNo
31[***]19‐L‐009454Motherway & NapletonBreast CancerNo
32[***]19‐L‐009508CLF/MBGALLNo
33[***]19‐L‐009528Nolan LawDuodenal AdenocarcinomaNo
34[***]19‐L‐009732Cavanagh Law GroupFollicular lymphoma/AMLNo
35[***]19‐L‐011510Motherway & NapletonBreast CancerNo
36[***]19‐L‐011682CLOBreast CancerNo
37[***]19‐L‐013486Tomasik Kotin KassermanBreast CancerNo
38[***]19‐L‐013488Tomasik Kotin KassermanBreast CancerNo
39[***]19‐L‐013493Tomasik Kotin KassermanBreast CancerNo
40[***]19‐L‐013517CLF/MBGBreast Cancer/CLLNo
41[***]19‐L‐013518CLF/MBGBreast CancerNo
42[***]19‐L‐013522CLF/MBGBreast CancerNo
43[***]19‐L‐013537RB/HMENHLNo
44[***]19‐L‐013538RB/HMENHLNo
45[***]19‐L‐013539RB/HMENHLNo
46[***]19‐L‐013540WSORALLNo
47[***]19‐L‐013541RB/HMEMMNo



CLAIMANT NAME(S)CASE NUMBERFIRMDIAGNOSIS/DIAGNOSES**Filed After 1/19
48[***]19‐L‐013544RB/HMEMMNo
49[***]19‐L‐013545RB/HMECLLNo
50[***]19‐L‐013545RB/HMENHLNo
51[***]19‐L‐013546Salvi, Schostok & PritchardNon‐Hodgkin's Lymphoma ‐ Diffuse
Large B‐Cell
No
52[***]19‐L‐013550Salvi, Schostok & PritchardBreast Cancer ‐ BilateralNo
53[***]19‐L‐013551Salvi, Schostok & PritchardLymphoma, Follicular & Large B‐Cell
Lymphoma
No
54[***]19‐L‐013552Salvi, Schostok & PritchardBreast CancerNo
55[***]19‐L‐013554WSORBreast CancerNo
56[***]19‐L‐013562RB/HMEALLNo
57[***]19‐L‐013568WSORLarge B Cell LymphomaNo
58[***]19‐L‐013575CLF/MBGBreast CancerNo
59[***]19‐L‐013576CLF/MBGNHLNo
60[***]19‐L‐013857CLF/MBGNHLNo
61[***]19‐L‐013860CLF/MBGBreast CancerNo
62[***]19‐L‐014265CLF/MBGWaldenstrom’s MacroglobulinemiaNo
63[***]20‐L‐005064TPMBbreast cancerNo
64[***]20‐L‐006260KJSChronic Myelogenous LeukemiaNo
65[***]20‐L‐007672CLONone ;Breast Cancer; histiocytosisNo
66[***]20‐L‐007672CLOHistiocytosisNo
67[***]20‐L‐008669RB/HMEMMNo
68[***]20‐L‐008671RB/HMEALLNo
69[***]20‐L‐008673RB/HMEBreast/LymphomeNo
70[***]20‐L‐008675RB/HMEBreast CancerNo
71[***]20‐L‐008676RB/HMEBreast CancerNo
72[***]20‐L‐008677RB/HMENHLNo
73[***]20‐L‐008678RB/HMEPancreatic CancerNo
74[***]20‐L‐008682RB/HMEMiscarriagesNo
75[***]20‐L‐008686Tomasik Kotin KassermanBreast Cancer and InfertilityNo
76[***]20‐L‐008688Tomasik Kotin KassermanBreast Cancer and InfertilityNo
77[***]20‐L‐008691Tomasik Kotin KassermanBreast CancerNo
78[***]20‐L‐008692Tomasik Kotin KassermanStomach CancerNo
79[***]20‐L‐008695RB/HMENHL (Burkett's)No
80[***]20‐L‐008699RB/HMEBreast cancer; 2 miscarriages;
infertility
No
81[***]20‐L‐008701RB/HMEBreast CancerNo
82[***]20‐L‐008702RB/HMETesticular CancerNo
83[***]20‐L‐008704RB/HMEFollicular LymphomaNo
84[***]20‐L‐008705RB/HMEBreast CancerNo
85[***]20‐L‐008706RB/HMEStomach CancerNo
86[***]20‐L‐008708RB/HMEMiscarriagesNo
87[***]20‐L‐008709RB/HMEMiscarriagesNo
88[***]20‐L‐008715RB/HMEBreast CancerNo
89[***]20‐L‐008716Motherway & NapletonBreast CancerNo
90[***]20‐L‐008718Motherway & NapletonIdiopathic Pulmonary FibrosisNo
91[***]20‐L‐008719KJSBreast CancerNo
92[***]20‐L‐008720RB/HMEMiscarriagesNo
93[***]20‐L‐008721KJSNHLNo



CLAIMANT NAME(S)CASE NUMBERFIRMDIAGNOSIS/DIAGNOSES**Filed After 1/19
94[***]20‐L‐008722RB/HMEMiscarriagesNo
95[***]20‐L‐008724CLF/MBGBreast CancerNo
96[***]20‐L‐008737TPMBpituitary adenomaNo
97[***]20‐L‐008740RB/HMEBreast CancerNo
98[***]20‐L‐008741RB/HMEBladder Cancer; Prostate CancerNo
99[***]20‐L‐008741RB/HMEMiscarriagesNo
100[***]20‐L‐008742RB/HMEBreast CancerNo
101[***]20‐L‐008743RB/HMENHLNo
102[***]20‐L‐008745RB/HMEALLNo
103[***]20‐L‐008746RB/HMEBreast CancerNo
104[***]20‐L‐008748RB/HMEBreast CancerNo
105[***]20‐L‐008749RB/HMEBreast CancerNo
106[***]20‐L‐008750RB/HMEBreast CancerNo
107[***]20‐L‐008752RB/HMEBreast CancerNo
108[***]20‐L‐008753RB/HMENHLNo
109[***]20‐L‐008755RB/HMEBreast CancerNo
110[***]20‐L‐008756RB/HMEKidney CancerNo
111[***]20‐L‐008757RB/HMEBreast CancerNo
112[***]20‐L‐008758RB/HMEBreast CancerNo
113[***]20‐L‐008759RB/HMEBreast CancerNo
114[***]20‐L‐008762RB/HMEBreast CancerNo
115[***]20‐L‐008764RB/HMEHLNo
116[***]20‐L‐008765RB/HMEHLNo
117[***]20‐L‐008766Power RogersBreast CancerNo
118[***]20‐L‐008766Power RogersLeukemiaNo
119[***]20‐L‐008769RB/HMEBreast CancerNo
120[***]20‐L‐008771RB/HMEAML/FertilityNo
121[***]20‐L‐008774Corboy & DemetrioBreast CancerNo
122[***]20‐L‐008776Salvi, Schostok & PritchardHodgkin's LymphomaNo
123[***]20‐L‐008779RB/HMEBreast CancerNo
124[***]20‐L‐008787Power RogersNHLNo
125[***]20‐L‐008791Wise MorrisseyBrain CancerNo
126[***]20‐L‐008792Wise MorrisseyBreast CancerNo
127[***]20‐L‐008794RB/HMENHLNo
128[***]20‐L‐008795RB/HMEKidney CancerNo
129[***]20‐L‐008797RB/HMEBreast CancerNo
130[***]20‐L‐008797RB/HMELymphomaNo
131[***]20‐L‐008799RB/HMELymphomaNo
132[***]20‐L‐008800RB/HMEBreast CancerNo
133[***]20‐L‐008803RB/HMEKidney CancerNo
134[***]20‐L‐008806RB/HMEBreast CancerNo
135[***]20‐L‐008809RB/HMEBreast CancerNo
136[***]20‐L‐008810RB/HMEMiscarriagesNo
137[***]20‐L‐008812RB/HMELeukemiaNo
138[***]20‐L‐008816Power RogersMultiple MyelomaNo
139[***]20‐L‐008825Power RogersBreast CancerNo
140[***]20‐L‐008826Power RogersNon Hodgkin's LymphomaNo
141[***]20‐L‐008828Power RogersNon Hodgkin's LymphomaNo



CLAIMANT NAME(S)CASE NUMBERFIRMDIAGNOSIS/DIAGNOSES**Filed After 1/19
142[***]20‐L‐008829Power RogersBreast CancerNo
143[***]20‐L‐008830Power RogersLeukemiaNo
144[***]20‐L‐008831Corboy & DemetrioAcute Lymphoblastic LeukemiaNo
145[***]20‐L‐008833Salvi, Schostok & PritchardNon‐Hodgkin's LymphomaNo
146[***]20‐L‐008834Power RogersBreast CancerNo
147[***]20‐L‐008835Power RogersBreast CancerNo
148[***]20‐L‐008838Power RogersBreast CancerNo
149[***]20‐L‐008840Power RogersBreast CancerNo
150[***]20‐L‐008841Cavanagh Law GroupBrain tumor/deathNo
151[***]20‐L‐008842Power RogersBreast CancerNo
152[***]20‐L‐008845CLF/MBGBreast CancerNo
153[***]20‐L‐008845CLF/MBGMiscrriageNo
154[***]20‐L‐008847Power RogersBreast CancerNo
155[***]20‐L‐008850Power RogersBreast CancerNo
156[***]20‐L‐008851Cavanagh Law GroupOsteosarcoma/deathNo
157[***]20‐L‐008853Power RogersMultiple MyelomaNo
158[***]20‐L‐008860Power RogersBreast CancerNo
159[***]20‐L‐008862Corboy & DemetrioBladder CancerNo
160[***]20‐L‐008868Smith LacienB‐cell Chronic Lymphocytic LeukemiaNo
161[***]20‐L‐008869Smith LacienNon‐Hodgkin's LymphomaNo
162[***]20-L-008870Smith LacienHodgkin's Lymphoma Stage 2bNo
163[***]20‐L‐008871Smith LacienFollicular Lymphoma; Tonsil CarcinomaNo
164[***]20‐L‐008872Smith LacienBlood Cancer; Uterine Cancer;
Myeloproliferative Neoplasim
No
165[***]20‐L‐008875Salvi, Schostok & PritchardBreast CancerNo
166[***]20‐L‐008876Salvi, Schostok & PritchardLeukemia Lymphocytic, ChronicNo
167[***]20‐L‐008879Salvi, Schostok & PritchardMiscarriages (4)No
168[***]20‐L‐008880Salvi, Schostok & PritchardBreast CancerNo
169[***]20‐L‐008881Salvi, Schostok & PritchardLeukemia (MDS)No
170[***]20‐L‐008882Smith LacienBreast CancerNo
171[***]20‐L‐008883Salvi, Schostok & PritchardBreast CancerNo
172[***]20‐L‐008884RB/HMEBreast CancerNo
173[***]20‐L‐008885RB/HMEMiscarriagesNo
174[***]20‐L‐008887RB/HMEMyeloid LeukemiaNo
175[***]20‐L‐008889Salvi, Schostok & PritchardLymphoma | Myelodysplastic
Syndromes
No
176[***]20‐L‐008891Smith LacienUterine Cancer; Breast CancerNo
177[***]20‐L‐008903Salvi, Schostok & PritchardLeukemia, Chronic MyeloidNo
178[***]20‐L‐008905Salvi, Schostok & PritchardBreast CancerNo
179[***]20‐L‐008909Smith LacienBreast CancerNo
180[***]20‐L‐008911Salvi, Schostok & PritchardBreast Cancer ‐ Stage 3 triple negativeNo
181[***]20‐L‐008914Salvi, Schostok & PritchardBreast CancerNo
182[***]20‐L‐008917Salvi, Schostok & PritchardBreast Cancer, Stage IIINo
183[***]20‐L‐008919Power RogersBreast CancerNo
184[***]20‐L‐008923Smith LacienBreast CancerNo
185[***]20‐L‐008925CLOBreast CancerNo
186[***]20‐L‐008929Salvi, Schostok & PritchardLung cancerNo
187[***]20‐L‐008930Salvi, Schostok & PritchardBreast cancerNo



CLAIMANT NAME(S)CASE NUMBERFIRMDIAGNOSIS/DIAGNOSES**Filed After 1/19
188[***]20‐L‐008932CLOBreast CancerNo
189[***]20‐L‐008933CLOStomach AdenocarcinomaNo
190[***]20‐L‐008934Salvi, Schostok & PritchardBreast CancerNo
191[***]20‐L‐008937CLOThyroid CancerNo
192[***]20‐L‐008943WSORBreast CancerNo
193[***]20‐L‐008945Smith LacienBreast Cancer; Lung CancerNo
194[***]20‐L‐008945Smith LacienNon‐Hodgkins LymphomaNo
195[***]20‐L‐008946Salvi, Schostok & PritchardBreast CancerNo
196[***]20‐L‐008948WSORBreast & Uterine CancerNo
197[***]20‐L‐008949Salvi, Schostok & PritchardBrain & Lung CancersNo
198[***]20‐L‐008950Salvi, Schostok & PritchardBrain tumorNo
199[***]20‐L‐008951Salvi, Schostok & PritchardLeukemia ‐ Acute MyeloidNo
200[***]20‐L‐008952WSORBladder CancerNo
201[***]20‐L‐008953Salvi, Schostok & PritchardLung Cancer (non‐small cell
adenocarcinoma)
No
202[***]20‐L‐008957WSORFybromyoxoid SarcomaNo
203[***]20‐L‐008958Salvi, Schostok & PritchardNon‐Hodgkin's LymphomaNo
204[***]20‐L‐008959WSORPancreatic CancerNo
205[***]20‐L‐008961Salvi, Schostok & PritchardGastrointestinal Cancer (stomach)No
206[***]20‐L‐008962Salvi, Schostok & PritchardStomach cancerNo
207[***]20‐L‐008966RB/HMEColon CancerNo
208[***]20‐L‐008971RB/HMEMiscarriagesNo
209[***]20‐L‐008989WSORProstate CancerNo
210[***]20‐L‐009000WSORProstate CancerNo
211[***]20‐L‐009006Smith LacienMultiple MyelomaNo
212[***]20‐L‐009012CLF/MBGMultiple MyelomaNo
213[***]20‐L‐009018CLF/MBGBreast CancerNo
214[***]20‐L‐009277RB/HMECancerNo
215[***]20‐L‐009296CLF/MBGBreast CancerNo
216[***]20‐L‐009380CLF/MBGHodgkin's LymphomaNo
217[***]20‐L‐012228CLF/MBGBreast cancerNo
218[***]20‐L‐012899CLF/MBGBreast Cancer, MiscarriageNo
219[***]21‐L_011277Smith LacienNon‐Hodgkin's LymphomaNo
220[***]21‐L‐001619McNabolaUterine/EndometrialNo
221[***]21‐L‐002646KaramanisFacial Adenoma?No
222[***]21‐L‐006899Salvi, Schostok & PritchardBreast CancerNo
223[***]21‐L‐008020RB/HMEBreast CancerNo
224[***]21‐L‐008023RB/HMEBreast CancerNo
225[***]21‐L‐008035RB/HMEBreast CancerNo
226[***]21‐L‐008090RB/HMEMultiple MyelomaNo
227[***]21‐L‐008685Salvi, Schostok & PritchardMultiple MyelomaNo
228[***]21‐L‐008692Salvi, Schostok & PritchardMantle Cell Lymphoma (NHL)No
229[***]21‐L‐008696Salvi, Schostok & PritchardBreast CancerNo
230[***]21‐L‐008698Salvi, Schostok & PritchardBreast CancerNo
231[***]21‐L‐009476Salvi, Schostok & PritchardBreast CancerNo
232[***]21‐L‐010808Salvi, Schostok & PritchardBreast CancerNo
233[***]21‐L‐011256CLF/MBGBreast CancerNo
234[***]21‐L‐011260CLF/MBGBreast CancerNo



CLAIMANT NAME(S)CASE NUMBERFIRMDIAGNOSIS/DIAGNOSES**Filed After 1/19
235[***]21‐L‐011261Smith LacienBreast CancerNo
236[***]21‐L‐011263CLF/MBGBreast CancerNo
237[***]21‐L‐011265CLF/MBGBreast CancerNo
238[***]21‐L‐011266Smith LacienLarge Cell B LymphomaNo
239[***]21‐L‐011268Smith LacienT‐Cell Acute Lymphocytic LeukemiaNo
240[***]21‐L‐011269Smith LacienNon‐Hodgkin's LymphomaNo
241[***]21‐L‐011270Smith LacienBreast Cancer; Fertility IssuesNo
242[***]21‐L‐011273CLF/MBGBreast CancerNo
243[***]21‐L‐011274Smith LacienLeukemia; Celiac Disease; AnemiaNo
244[***]21‐L‐011276CLF/MBGBreast CancerNo
245[***]21‐L‐011278CLF/MBGBreast CancerNo
246[***]21‐L‐011279Smith LacienNon‐Hodgkins LymphomaNo
247[***]21‐L‐011280Smith LacienBreast CancerNo
248[***]21‐L‐011281Smith LacienNon‐Hodgkin's Lymphoma; Breast
Cancer
No
249[***]21‐L‐011283Smith LacienMast Cell Leukemia, Advanced
Systemic Mastocytosis, Myelodysplastic Syndrome.
No
250[***]21‐L‐011284Smith LacienNon‐Hodgkin's LymphomaNo
251[***]21‐L‐011285Smith LacienBreast CancerNo
252[***]21‐L‐011286Smith LacienProstate Cancer; Non‐Hodgkins
Lymphoma
No
253[***]21‐L‐011288Smith LacienLarge Cell B Type Non‐Hodgkin's
Lymphoma
No
254[***]21‐L‐011290Smith LacienBreast CancerNo
255[***]21‐L‐011292Smith LacienBreast CancerNo
256[***]21‐L‐011293CLF/MBGHogkin's LymphomaNo
257[***]21‐L‐011293CLF/MBGHogkin's LymphomaNo
258[***]21‐L‐011294Smith LacienBreast CancerNo
259[***]21‐L‐011295Smith LacienIntertility; Breast CancerNo
260[***]21‐L‐011298Smith LacienBreast CancerNo
261[***]21‐L‐011299Smith LacienBreast CancerNo
262[***]21‐L‐011300CLF/MBGBreast CancerNo
263[***]21‐L‐011301Smith LacienLarynx Cancer; LymphomaNo
264[***]21‐L‐011302Smith LacienBreast Cancer; Paillary Thyroid
Carcinoma; Basal Cell Carcinoma
No
265[***]21‐L‐011303CLF/MBGNHLNo
266[***]21‐L‐011304CLF/MBGBreast CancerNo
267[***]21‐L‐011305Smith LacienBreast CancerNo
268[***]21‐L‐011305Smith LacienChronic Myelogenous LeukemiaNo
269[***]21‐L‐011306CLF/MBGBreast CancerNo
270[***]21‐L‐011306CLF/MBGBreast CancerNo
271[***]21‐L‐011308CLF/MBGStomach CancerNo
272[***]21‐L‐011309CLF/MBGMiscarriagesNo
273[***]21‐L‐011313CLF/MBGCarcinoid TumorNo
274[***]21‐L‐011313CLF/MBGMyelodysplastic SyndromeNo
275[***]21‐L‐011317CLF/MBGBreast CancerNo
276[***]21‐L‐011318Tomasik Kotin KassermanInfertilityNo
277[***]21‐L‐011319CLF/MBGBreast CancerNo
278[***]21‐L‐011319CLF/MBGBreast CancerNo



CLAIMANT NAME(S)CASE NUMBERFIRMDIAGNOSIS/DIAGNOSES**Filed After 1/19
279[***]21‐L‐011319CLF/MBGSmouldering MyelomaNo
280[***]21‐L‐011320Tomasik Kotin KassermanBreast CancerNo
281[***]21‐L‐011322CLF/MBGBreast CancerNo
282[***]21‐L‐011323Tomasik Kotin KassermanMultiple MyelomiaNo
283[***]21‐L‐011324Tomasik Kotin KassermanBreast CancerNo
284[***]21‐L‐011326Tomasik Kotin KassermanInfertilityNo
285[***]21‐L‐011327Tomasik Kotin KassermanLeukemiaNo
286[***]21‐L‐011329Tomasik Kotin KassermanStomach CancerNo
287[***]21‐L‐011330RB/HMEBreast CancerNo
288[***]21‐L‐011331Tomasik Kotin KassermanBreast CancerNo
289[***]21‐L‐011332Tomasik Kotin KassermanBreast CancerNo
290[***]21‐L‐011333Tomasik Kotin KassermanBirth DefectsNo
291[***]21‐L‐011333Tomasik Kotin KassermanBirth DefectsNo
292[***]21‐L‐011333Tomasik Kotin KassermanBirth DefectsNo
293[***]21‐L‐011333Tomasik Kotin KassermanFertility IssuesNo
294[***]21‐L‐011334CLF/MBGBreast CancerNo
295[***]21‐L‐011335RB/HMENHLNo
296[***]21‐L‐011336RB/HMENHLNo
297[***]21‐L‐011337RB/HMEALLNo
298[***]21‐L‐011338Salvi, Schostok & PritchardNeuroblastomaNo
299[***]21‐L‐011338Salvi, Schostok & PritchardNon‐Hodgkin's Lymphoma, Stage IINo
300[***]21‐L‐011343Tomasik Kotin KassermanBreast CancerNo
301[***]21‐L‐011347Salvi, Schostok & PritchardBreast CancerNo
302[***]21‐L‐011348CLF/MBGBreast CancerNo
303[***]21‐L‐011349Tomasik Kotin KassermanInfertilityNo
304[***]21‐L‐011350Tomasik Kotin KassermanFertility IssuesNo
305[***]21‐L‐011351Tomasik Kotin KassermanBladder CancerNo
306[***]21‐L‐011352CLF/MBGBreast CancerNo
307[***]21‐L‐011353Salvi, Schostok & PritchardBreast Cancer X2No
308[***]21‐L‐011354CLF/MBGBreast CancerNo
309[***]21‐L‐011355CLF/MBGBreast CancerNo
310[***]21‐L‐011356Salvi, Schostok & PritchardLymphomaNo
311[***]21‐L‐011357CLF/MBGBreast CancerNo
312[***]21‐L‐011359Salvi, Schostok & PritchardBreast CancerNo
313[***]21‐L‐011360CLF/MBGBreast CancerNo
314[***]21‐L‐011361Salvi, Schostok & PritchardBreast CancerNo
315[***]21‐L‐011363CLF/MBGBreast Cancer, MiscarriagesNo
316[***]21‐L‐011364CLF/MBGBreast Cancer (Paget's Disease)No
317[***]21‐L‐011368Salvi, Schostok & PritchardNon‐Hodgkin's Lymphoma X2No
318[***]21‐L‐011369RB/HMEHLNo
319[***]21‐L‐011370CLF/MBGBreast CancerNo
320[***]21‐L‐011371RB/HMEBreast CancerNo
321[***]21‐L‐011372CLF/MBGWaldenstrom’s MacroglobulinemiaNo
322[***]21‐L‐011375Salvi, Schostok & PritchardBreast cancer | 2 Brain TumorsNo
323[***]21‐L‐011376CLF/MBGBreast CancerNo
324[***]21‐L‐011380Salvi, Schostok & PritchardLeukemia, LymphocyticNo
325[***]21‐L‐011381CLF/MBGBreast Cancer, MiscarriageNo
326[***]21‐L‐011384CLF/MBGBreast CancerNo



CLAIMANT NAME(S)CASE NUMBERFIRMDIAGNOSIS/DIAGNOSES**Filed After 1/19
327[***]21‐L‐011385Salvi, Schostok & PritchardStomach cancerNo
328[***]21‐L‐011386Salvi, Schostok & PritchardBreast Cancer x2No
329[***]21‐L‐011388CLF/MBGBreast Cancer, MiscarriagesNo
330[***]21‐L‐011389Salvi, Schostok & PritchardBreast cancer & 11 MiscarriagesNo
331[***]21‐L‐011391Salvi, Schostok & PritchardBreast CancerNo
332[***]21‐L‐011392CLF/MBGBreast CancerNo
333[***]21‐L‐011393RB/HMEBreast CancerNo
334[***]21‐L‐011395Salvi, Schostok & PritchardLymphoma, Splenic Marginal Zone B
Cel
No
335[***]21‐L‐011396Salvi, Schostok & PritchardBreast cancerNo
336[***]21‐L‐011397CLF/MBGBreast CancerNo
337[***]21‐L‐011399RB/HMEBreast CancerNo
338[***]21‐L‐011401CLF/MBGBreast CancerNo
339[***]21‐L‐011402Salvi, Schostok & PritchardBreast Cancer | Non‐Hodgkin's
Lymphoma
No
340[***]21‐L‐011403CLF/MBGBreast Cancer, MiscarriageNo
341[***]21‐L‐011404CLF/MBGBreast CancerNo
342[***]21‐L‐011405Salvi, Schostok & PritchardBreast cancerNo
343[***]21‐L‐011406Salvi, Schostok & PritchardBreast CancerNo
344[***]21‐L‐011407CLF/MBGHodgkin's LymphomaNo
345[***]21‐L‐011407CLF/MBGMyelodysplastic Syndrome; AMLNo
346[***]21‐L‐011409Salvi, Schostok & PritchardBreast cancerNo
347[***]21‐L‐011411Salvi, Schostok & PritchardBreast CancerNo
348[***]21‐L‐011412Salvi, Schostok & PritchardBreast Cancer ‐ Ductal carcinoma in
situ
No
349[***]21‐L‐011413CLF/MBGBreast CancerNo
350[***]21‐L‐011415Salvi, Schostok & PritchardBreast cancer |No
351[***]21‐L‐011416CLF/MBGFollicular Lymphoma; Diffuse Large B‐
Cell Lymphoma
No
352[***]21‐L‐011417Salvi, Schostok & PritchardBreast Cancer X2No
353[***]21‐L‐011419CLF/MBGHodgkin's LymphomaNo
354[***]21‐L‐011421Salvi, Schostok & PritchardMultiple MyelomaNo
355[***]21‐L‐011423Salvi, Schostok & PritchardNon‐Hodgkins LymphomaNo
356[***]21‐L‐011424Salvi, Schostok & PritchardBreast cancerNo
357[***]21‐L‐011425CLF/MBGCMLNo
358[***]21‐L‐011426Salvi, Schostok & PritchardHodgkin's Lymphoma, Nodular
Sclerosis
No
359[***]21‐L‐011429CLF/MBGBreast CancerNo
360[***]21‐L‐011431Salvi, Schostok & PritchardBreast cancer | 3 MiscarriageNo
361[***]21‐L‐011432RB/HMEBreast CancerNo
362[***]21‐L‐011433RB/HMEPCVNo
363[***]21‐L‐011434CLF/MBGBreast CancerNo
364[***]21‐L‐011435RB/HMEPCVNo
365[***]21‐L‐011436Salvi, Schostok & PritchardBreast CancerNo
366[***]21‐L‐011437RB/HMEBreast CancerNo
367[***]21‐L‐011439RB/HMEBreast CancerNo
368[***]21‐L‐011440CLF/MBGBreast CancerNo
369[***]21‐L‐011440CLF/MBGCMLNo
370[***]21‐L‐011442RB/HMEBreast CancerNo



CLAIMANT NAME(S)CASE NUMBERFIRMDIAGNOSIS/DIAGNOSES**Filed After 1/19
371[***]21‐L‐011443Salvi, Schostok & PritchardBreast CancerNo
372[***]21‐L‐011444Salvi, Schostok & PritchardHodgkin's lymphomaNo
373[***]21‐L‐011445RB/HMEBreast CancerNo
374[***]21‐L‐011447Salvi, Schostok & PritchardBreast cancerNo
375[***]21‐L‐011448RB/HMENHLNo
376[***]21‐L‐011450RB/HMEBreast Cancer; Uterine Cancer; Lung
Cancer
No
377[***]21‐L‐011452RB/HMEBreast CancerNo
378[***]21‐L‐011453Salvi, Schostok & PritchardBreast CancerNo
379[***]21‐L‐011454RB/HMECMLNo
380[***]21‐L‐011455Salvi, Schostok & PritchardNon‐Hodgkin's LymphomaNo
381[***]21‐L‐011456RB/HMEBreast CancerNo
382[***]21‐L‐011457CLF/MBGColon CancerNo
383[***]21‐L‐011458RB/HMEBreast CancerNo
384[***]21‐L‐011459Salvi, Schostok & PritchardBreast CancerNo
385[***]21‐L‐011460CLF/MBGColon CancerNo
386[***]21‐L‐011461RB/HMEBreast CancerNo
387[***]21‐L‐011462RB/HMEBreast CancerNo
388[***]21‐L‐011463CLF/MBGBreast CancerNo
389[***]21‐L‐011465RB/HMEEssential ThrombocythemiaNo
390[***]21‐L‐011467Salvi, Schostok & PritchardLeukemia MyelofibrosisNo
391[***]21‐L‐011468RB/HMEBreast CancerNo
392[***]21‐L‐011469RB/HMEAMLNo
393[***]21‐L‐011470RB/HMECLLNo
394[***]21‐L‐011471RB/HMEBreast CancerNo
395[***]21‐L‐011472RB/HMEBreast CancerNo
396[***]21‐L‐011473Salvi, Schostok & PritchardBrain Cancer (Ependymoma)No
397[***]21‐L‐011474RB/HMECLL/SLLNo
398[***]21‐L‐011475Salvi, Schostok & PritchardBreast Cancer X2No
399[***]21‐L‐011476Salvi, Schostok & PritchardBrain CancerNo
400[***]21‐L‐011477RB/HMEBreast CancerNo
401[***]21‐L‐011478Salvi, Schostok & PritchardBreast cancerNo
402[***]21‐L‐011479RB/HMELymphomaNo
403[***]21‐L‐011480Salvi, Schostok & PritchardBrain TumorNo
404[***]21‐L‐011481RB/HMEBreast CancerNo
405[***]21‐L‐011483Salvi, Schostok & PritchardBreast CancerNo
406[***]21‐L‐011484Salvi, Schostok & PritchardLeukemia, LymphocyticNo
407[***]21‐L‐011485Salvi, Schostok & PritchardBreast CancerNo
408[***]21‐L‐011486Salvi, Schostok & PritchardBreast CancerNo
409[***]21‐L‐011487Salvi, Schostok & PritchardBreast CancerNo
410[***]21‐L‐011488Salvi, Schostok & PritchardMultiple MyelomaNo
411[***]21‐L‐011490Salvi, Schostok & PritchardLung CancerNo
412[***]21‐L‐011492Salvi, Schostok & PritchardNon‐Hodgkin's Lymphoma x2No
413[***]21‐L‐011493RB/HMENHLNo
414[***]21‐L‐011494Salvi, Schostok & PritchardLeukemia (Hairy Cell)No
415[***]21‐L‐011495Salvi, Schostok & PritchardBreast CancerNo
416[***]21‐L‐011496RB/HMEMiscarriagesNo
417[***]21‐L‐011498RB/HMELung CancerNo



CLAIMANT NAME(S)CASE NUMBERFIRMDIAGNOSIS/DIAGNOSES**Filed After 1/19
418[***]21‐L‐011499RB/HMEBreast CancerNo
419[***]21‐L‐011500Salvi, Schostok & Pritchardbreast cancerNo
420[***]21‐L‐011501Salvi, Schostok & PritchardLung CancerNo
421[***]21‐L‐011502Salvi, Schostok & PritchardNon‐Hodgkins LymphomaNo
422[***]21‐L‐011503Salvi, Schostok & PritchardBreast CancerNo
423[***]21‐L‐011504Salvi, Schostok & PritchardLeukemia, Lymphocytic, ChronicNo
424[***]21‐L‐011506Salvi, Schostok & PritchardBreast CancerNo
425[***]21‐L‐011507Salvi, Schostok & PritchardBreast CancerNo
426[***]21‐L‐011508Salvi, Schostok & PritchardBreast cancerNo
427[***]21‐L‐011509Salvi, Schostok & PritchardBreast CancerNo
428[***]21‐L‐011510Salvi, Schostok & PritchardBreast cancerNo
429[***]21‐L‐011511Salvi, Schostok & PritchardBreast CancerNo
430[***]21‐L‐011512RB/HMEBreast CancerNo
431[***]21‐L‐011512RB/HMEBreast CancerNo
432[***]21‐L‐011512RB/HMEKidney CancerNo
433[***]21‐L‐011513Salvi, Schostok & PritchardHodgkin's Disease | 2 MiscarriagesNo
434[***]21‐L‐011515Salvi, Schostok & PritchardBreast cancerNo
435[***]21‐L‐011516Salvi, Schostok & PritchardMultiple MyelomaNo
436[***]21‐L‐011517Salvi, Schostok & PritchardBreast cancerNo
437[***]21‐L‐011521RB/HMEThyroid CancerNo
438[***]21‐L‐011523RB/HMEBreast CancerNo
439[***]21‐L‐011524RB/HMEBreast CancerNo
440[***]21‐L‐011528RB/HMEMiscarriagesNo
441[***]21‐L‐011529RB/HMEBreast CancerNo
442[***]21‐L‐011530RB/HMEMMNo
443[***]21‐L‐011531RB/HMEBreast CancerNo
444[***]21‐L‐011532RB/HMEBreast CancerNo
445[***]21‐L‐011533RB/HMEBreast CancerNo
446[***]21‐L‐011534RB/HMEBreast CancerNo
447[***]21‐L‐011537RB/HMEBreast CancerNo
448[***]21‐L‐011538RB/HMEMMNo
449[***]21‐L‐011540RB/HMECMLNo
450[***]21‐L‐011541Salvi, Schostok & PritchardBreast Cancer, Stage IVNo
451[***]21‐L‐011542Salvi, Schostok & PritchardMultiple MyelomaNo
452[***]21‐L‐011544RB/HMEBreast CancerNo
453[***]21‐L‐011545RB/HMEBreast CancerNo
454[***]21‐L‐011546Salvi, Schostok & PritchardPancreatic Cancer, Mets. Stage IVNo
455[***]21‐L‐011547RB/HMEKidney CancerNo
456[***]21‐L‐011548RB/HMENHLNo
457[***]21‐L‐011549RB/HMEBreast CancerNo
458[***]21‐L‐011550RB/HMEBreast CancerNo
459[***]21‐L‐011551Salvi, Schostok & PritchardLung CancerNo
460[***]21‐L‐011552RB/HMECLLNo
461[***]21‐L‐011553RB/HMEMMNo
462[***]21‐L‐011554Salvi, Schostok & PritchardBreast cancerNo
463[***]21‐L‐011557RB/HMECLLNo
464[***]21‐L‐011557RB/HMECLLNo
465[***]21‐L‐011558Salvi, Schostok & PritchardNon‐Hodgkins LymphomaNo



CLAIMANT NAME(S)CASE NUMBERFIRMDIAGNOSIS/DIAGNOSES**Filed After 1/19
466[***]21‐L‐011559RB/HMENHLNo
467[***]21‐L‐011560RB/HMEBreast CancerNo
468[***]21‐L‐011562RB/HMECLLNo
469[***]21‐L‐011563Salvi, Schostok & PritchardBreast cancerNo
470[***]21‐L‐011564RB/HMENHLNo
471[***]21‐L‐011565Salvi, Schostok & PritchardBreast cancerNo
472[***]21‐L‐011566RB/HMENHLNo
473[***]21‐L‐011567RB/HMENHLNo
474[***]21‐L‐011568RB/HMEHairy Cell LeukemiaNo
475[***]21‐L‐011571Salvi, Schostok & PritchardBreast Cancer | Pancreatic CancerNo
476[***]21‐L‐011573Salvi, Schostok & PritchardBreast CancerNo
477[***]21‐L‐011574RB/HMEBreast CancerNo
478[***]21‐L‐011575Salvi, Schostok & PritchardBreast CancerNo
479[***]21‐L‐011576RB/HMEBreast CancerNo
480[***]21‐L‐011577Salvi, Schostok & PritchardLeukemia, Chronic LymphocyticNo
481[***]21‐L‐011578RB/HMENHLNo
482[***]21‐L‐011579RB/HMECLLNo
483[***]21‐L‐011580RB/HMEBreast CancerNo
484[***]21‐L‐011581RB/HMENHLNo
485[***]21‐L‐011582RB/HMEMMNo
486[***]21‐L‐011584Salvi, Schostok & PritchardBreast Cancer | Lung CancerNo
487[***]21‐L‐011585RB/HMEBreast CancerNo
488[***]21‐L‐011586Salvi, Schostok & PritchardLeukemiaNo
489[***]21‐L‐011587RB/HMEBreast CancerNo
490[***]21‐L‐011588RB/HMENHLNo
491[***]21‐L‐011589Salvi, Schostok & PritchardPancreatic CancerNo
492[***]21‐L‐011590RB/HMEMultiple MyelomaNo
493[***]21‐L‐011592RB/HMECLLNo
494[***]21‐L‐011593RB/HMEBreast CancerNo
495[***]21‐L‐011594RB/HMECMMLNo
496[***]21‐L‐011596RB/HMEBreast CancerNo
497[***]21‐L‐011597RB/HMEBreast CancerNo
498[***]21‐L‐011598RB/HMENHLNo
499[***]21‐L‐011600Salvi, Schostok & PritchardLymphomaNo
500[***]21‐L‐011602RB/HMEBreast CancerNo
501[***]21‐L‐011603RB/HMEMM/LeukemiaNo
502[***]21‐L‐011604Salvi, Schostok & PritchardBreast CancerNo
503[***]21‐L‐011605RB/HMEBreast CancerNo
504[***]21‐L‐011606RB/HMEBreast CancerNo
505[***]21‐L‐011607Salvi, Schostok & PritchardLeukemiaNo
506[***]21‐L‐011608RB/HMEBreast CancerNo
507[***]21‐L‐011609Salvi, Schostok & PritchardBreast cancer x4No
508[***]21‐L‐011611Salvi, Schostok & PritchardBreast CancerNo
509[***]21‐L‐011614RB/HMEBreast CancerNo
510[***]21‐L‐011615Salvi, Schostok & PritchardBreast Cancer | LymphomaNo
511[***]21‐L‐011616RB/HMEAMLNo
512[***]21‐L‐011617Salvi, Schostok & PritchardPancreatic CancerNo
513[***]21‐L‐011618RB/HMENHL (Waldenstroms)No



CLAIMANT NAME(S)CASE NUMBERFIRMDIAGNOSIS/DIAGNOSES**Filed After 1/19
514[***]21‐L‐011619RB/HMEBreast CancerNo
515[***]21‐L‐011620Salvi, Schostok & PritchardLung CancerNo
516[***]21‐L‐011621Salvi, Schostok & PritchardNon‐Hodgkin's LymphomaNo
517[***]21‐L‐011622RB/HMENHLNo
518[***]21‐L‐011623RB/HMEAMLNo
519[***]21‐L‐011624Salvi, Schostok & PritchardLeukemiaNo
520[***]21‐L‐011625RB/HMEMiscarriagesNo
521[***]21‐L‐011626Salvi, Schostok & PritchardNon Hodgkin's LymphomaNo
522[***]21‐L‐011627Salvi, Schostok & PritchardLymphomaNo
523[***]21‐L‐011628RB/HMEBreast CancerNo
524[***]21‐L‐011629RB/HMEHLNo
525[***]21‐L‐011630RB/HMELeukemiaNo
526[***]21‐L‐011631Salvi, Schostok & PritchardBreast CancerNo
527[***]21‐L‐011632RB/HMEMiscarriagesNo
528[***]21‐L‐011633Salvi, Schostok & PritchardBrain, Prostate & Lung CancersNo
529[***]21‐L‐011634RB/HMEBreast CancerNo
530[***]21‐L‐011635RB/HMEBreast CancerNo
531[***]21‐L‐011636Salvi, Schostok & PritchardLung Cancer, Non‐Small CellNo
532[***]21‐L‐011637RB/HMEBreast CancerNo
533[***]21‐L‐011638RB/HMEHodgkin's Lymphoma; prostate
cancer;lymph node
No
534[***]21‐L‐011639Salvi, Schostok & PritchardBreast CancerNo
535[***]21‐L‐011640RB/HMEBreast CancerNo
536[***]21‐L‐011641RB/HMEBirth DefectNo
537[***]21‐L‐011641RB/HMENHLNo
538[***]21‐L‐011642Salvi, Schostok & PritchardNeuroblastomaNo
539[***]21‐L‐011643RB/HMEFertilityNo
540[***]21‐L‐011644RB/HMECLLNo
541[***]21‐L‐011645RB/HMEBreast CancerNo
542[***]21‐L‐011647RB/HMEBreast CancerNo
543[***]21‐L‐011648Salvi, Schostok & PritchardBreast CancerNo
544[***]21‐L‐011649RB/HMEBirth DefectNo
545[***]21‐L‐011650